Skip to main content

Table 1 Patient characteristics

From: Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Characteristic Mt + (n= 121) Mt – (n= 163) All (n= 284)
  No. % No. % No. %
Age, years       
 Median (range) 66 (32–87)   65 (23–83)   65 (23–87)  
 < 70 97 80 134 82 231 81
 ≥ 70       
  24 20 29 18 53 19
Gender       
 Male 43 36 125 77 168 59
 Female 78 64 38 23 116 41
ECOG PS       
 0-1 103 85 135 83 238 84
 > 2 18 15 28 17 46 16
Smoking status       
 Yes 50 41 124 76 174 61
 No 71 59 39 24 110 39
Stage       
 IIIB 6 5 19 12 25 9
 IV 115 95 144 88 259 91
EGFR mutation       
 Exon 19 deletion 59 49    59 21
 Exon 21 L858R 57 47    57 20
 Exon 18 G719X 5 4    5 2
 Wild type    163 100 163 57
PCV       
 Median (range) 1.6 (0.1-110.0)   2.3 (0.1-80.0)   2.0 (0.1-110.0)  
 < 2.2 ng/ml 72 60 78 48 150 53
 ≥ 2.2 ng/ml 49 40 85 52 134 47
CEA       
 Median (range) 8 (0.7-11942)   7 (0.5-14985)   7.4 (0.5-14985)  
 < 5.0 ng/ml 45 37 63 39 108 38
 ≥ 5.0 ng/ml 76 63 100 61 176 62
  1. EGFR: epidermal growth factor receptor, Mt+: mutant EGFR, Mt-: wild-type EGFR, PCV: pretreatment CYFRA 21–1 value.